The effect of cholesterol reduction with cholestyramine on renal function

Abhijit V. Kshirsagar, David A. Shoham, Heejung Bang, Susan L. Hogan, Ross J. Simpson, Romulo E. Colindres

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Epidemiological studies suggest that dyslipidemia is an independent risk factor for the development of renal insufficiency in otherwise healthy individuals. Yet, data on the effect of cholesterol reduction are lacking in this population. We performed a secondary analysis of a large existing cohort to determine whether treatment with cholestyramine improved renal function compared with placebo. Methods: A total of 3,603 middle-aged men from the Lipid Research Clinics Coronary Primary Prevention Trial comprised the study group: 1,806 men were randomly assigned to treatment with cholestyramine, and 1,797 men, placebo. The primary outcome is difference in glomerular filtration rates between the 2 groups. Results: A total of 1,806 men were randomly assigned to treatment with cholestyramine, and 1,797 men, placebo. For the entire group, the estimated mean difference in glomerular filtration rates between the cholestyramine and placebo groups was 0.39 mL/min/1.73 m2 (0.007 mL/s/1.73 m2; P = 0.28) during a follow-up period of more than 8 years. Conclusion: Cholesterol reduction with cholestyramine treatment did not meaningfully affect renal function compared with placebo in the present analysis. Prospective intervention trials are needed to determine whether decreasing serum cholesterol levels benefits kidney function in otherwise healthy individuals.

Original languageEnglish (US)
Pages (from-to)812-819
Number of pages8
JournalAmerican Journal of Kidney Diseases
Volume46
Issue number5
DOIs
StatePublished - Nov 2005
Externally publishedYes

Fingerprint

Cholestyramine Resin
Cholesterol
Placebos
Kidney
Glomerular Filtration Rate
Primary Prevention
Therapeutics
Dyslipidemias
Renal Insufficiency
Epidemiologic Studies
Lipids
Serum
Research
Population

Keywords

  • Hypercholesterolemia
  • Randomized controlled trial
  • Renal function

ASJC Scopus subject areas

  • Nephrology

Cite this

Kshirsagar, A. V., Shoham, D. A., Bang, H., Hogan, S. L., Simpson, R. J., & Colindres, R. E. (2005). The effect of cholesterol reduction with cholestyramine on renal function. American Journal of Kidney Diseases, 46(5), 812-819. https://doi.org/10.1053/j.ajkd.2005.08.012

The effect of cholesterol reduction with cholestyramine on renal function. / Kshirsagar, Abhijit V.; Shoham, David A.; Bang, Heejung; Hogan, Susan L.; Simpson, Ross J.; Colindres, Romulo E.

In: American Journal of Kidney Diseases, Vol. 46, No. 5, 11.2005, p. 812-819.

Research output: Contribution to journalArticle

Kshirsagar, AV, Shoham, DA, Bang, H, Hogan, SL, Simpson, RJ & Colindres, RE 2005, 'The effect of cholesterol reduction with cholestyramine on renal function', American Journal of Kidney Diseases, vol. 46, no. 5, pp. 812-819. https://doi.org/10.1053/j.ajkd.2005.08.012
Kshirsagar, Abhijit V. ; Shoham, David A. ; Bang, Heejung ; Hogan, Susan L. ; Simpson, Ross J. ; Colindres, Romulo E. / The effect of cholesterol reduction with cholestyramine on renal function. In: American Journal of Kidney Diseases. 2005 ; Vol. 46, No. 5. pp. 812-819.
@article{6227975561b440729494049887288cfe,
title = "The effect of cholesterol reduction with cholestyramine on renal function",
abstract = "Background: Epidemiological studies suggest that dyslipidemia is an independent risk factor for the development of renal insufficiency in otherwise healthy individuals. Yet, data on the effect of cholesterol reduction are lacking in this population. We performed a secondary analysis of a large existing cohort to determine whether treatment with cholestyramine improved renal function compared with placebo. Methods: A total of 3,603 middle-aged men from the Lipid Research Clinics Coronary Primary Prevention Trial comprised the study group: 1,806 men were randomly assigned to treatment with cholestyramine, and 1,797 men, placebo. The primary outcome is difference in glomerular filtration rates between the 2 groups. Results: A total of 1,806 men were randomly assigned to treatment with cholestyramine, and 1,797 men, placebo. For the entire group, the estimated mean difference in glomerular filtration rates between the cholestyramine and placebo groups was 0.39 mL/min/1.73 m2 (0.007 mL/s/1.73 m2; P = 0.28) during a follow-up period of more than 8 years. Conclusion: Cholesterol reduction with cholestyramine treatment did not meaningfully affect renal function compared with placebo in the present analysis. Prospective intervention trials are needed to determine whether decreasing serum cholesterol levels benefits kidney function in otherwise healthy individuals.",
keywords = "Hypercholesterolemia, Randomized controlled trial, Renal function",
author = "Kshirsagar, {Abhijit V.} and Shoham, {David A.} and Heejung Bang and Hogan, {Susan L.} and Simpson, {Ross J.} and Colindres, {Romulo E.}",
year = "2005",
month = "11",
doi = "10.1053/j.ajkd.2005.08.012",
language = "English (US)",
volume = "46",
pages = "812--819",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - The effect of cholesterol reduction with cholestyramine on renal function

AU - Kshirsagar, Abhijit V.

AU - Shoham, David A.

AU - Bang, Heejung

AU - Hogan, Susan L.

AU - Simpson, Ross J.

AU - Colindres, Romulo E.

PY - 2005/11

Y1 - 2005/11

N2 - Background: Epidemiological studies suggest that dyslipidemia is an independent risk factor for the development of renal insufficiency in otherwise healthy individuals. Yet, data on the effect of cholesterol reduction are lacking in this population. We performed a secondary analysis of a large existing cohort to determine whether treatment with cholestyramine improved renal function compared with placebo. Methods: A total of 3,603 middle-aged men from the Lipid Research Clinics Coronary Primary Prevention Trial comprised the study group: 1,806 men were randomly assigned to treatment with cholestyramine, and 1,797 men, placebo. The primary outcome is difference in glomerular filtration rates between the 2 groups. Results: A total of 1,806 men were randomly assigned to treatment with cholestyramine, and 1,797 men, placebo. For the entire group, the estimated mean difference in glomerular filtration rates between the cholestyramine and placebo groups was 0.39 mL/min/1.73 m2 (0.007 mL/s/1.73 m2; P = 0.28) during a follow-up period of more than 8 years. Conclusion: Cholesterol reduction with cholestyramine treatment did not meaningfully affect renal function compared with placebo in the present analysis. Prospective intervention trials are needed to determine whether decreasing serum cholesterol levels benefits kidney function in otherwise healthy individuals.

AB - Background: Epidemiological studies suggest that dyslipidemia is an independent risk factor for the development of renal insufficiency in otherwise healthy individuals. Yet, data on the effect of cholesterol reduction are lacking in this population. We performed a secondary analysis of a large existing cohort to determine whether treatment with cholestyramine improved renal function compared with placebo. Methods: A total of 3,603 middle-aged men from the Lipid Research Clinics Coronary Primary Prevention Trial comprised the study group: 1,806 men were randomly assigned to treatment with cholestyramine, and 1,797 men, placebo. The primary outcome is difference in glomerular filtration rates between the 2 groups. Results: A total of 1,806 men were randomly assigned to treatment with cholestyramine, and 1,797 men, placebo. For the entire group, the estimated mean difference in glomerular filtration rates between the cholestyramine and placebo groups was 0.39 mL/min/1.73 m2 (0.007 mL/s/1.73 m2; P = 0.28) during a follow-up period of more than 8 years. Conclusion: Cholesterol reduction with cholestyramine treatment did not meaningfully affect renal function compared with placebo in the present analysis. Prospective intervention trials are needed to determine whether decreasing serum cholesterol levels benefits kidney function in otherwise healthy individuals.

KW - Hypercholesterolemia

KW - Randomized controlled trial

KW - Renal function

UR - http://www.scopus.com/inward/record.url?scp=27144474760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27144474760&partnerID=8YFLogxK

U2 - 10.1053/j.ajkd.2005.08.012

DO - 10.1053/j.ajkd.2005.08.012

M3 - Article

C2 - 16253720

AN - SCOPUS:27144474760

VL - 46

SP - 812

EP - 819

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 5

ER -